Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain.
Vigil Neuroscience is tracked in the Tech.eu funding database. Based in Watertown, United States; active in Healthtech. Acquired by Sanofi in 2025. Data as of 25 Aug 2026.
